Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Olesen

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Current Opinion in Drug Discovery & Development|December 1, 2001
The use of bioisosteric groups in lead optimizationP H Olesen
Sygeplejersken|March 23, 1972
[Question without answer]P H Olesen
Current Medicinal Chemistry|April 3, 2001
Agonists at the alpha4beta2 nicotinic acetylcholine receptors: structure-activity relationships and molecular modellingJ E Tønder, P H Olesen
Bioorganic & Medicinal Chemistry|November 5, 1998
3-(5-Alkylamino-4-isoxazolyl)-1,2,5,6-tetrahydropyridines: a novel class of central nicotinic receptor ligandsP H Olesen, M D Swedberg, K Rimvall
Journal of Computer-Aided Molecular Design|April 6, 2001
An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled byJ E Tønder, P H Olesen, J B Hansen, et al.
Bioorganic & Medicinal Chemistry|July 15, 2000
Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptorsP H Olesen, J E Tønder, J B Hansen, et al.
Journal of Medicinal Chemistry|December 10, 1999
Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modelingJ E Tønder, J B Hansen, M Begtrup, et al.
Chirality|January 1, 1997
Synthesis and structural determination of stereoisomers of muscarinic ligands of the (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloalkane typeP H Olesen, P Sauerberg, T G Petersen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
M1 receptor agonist activity is not a requirement for muscarinic antinociceptionM J Sheardown, H E Shannon, M D Swedberg, et al.
Journal of Medicinal Chemistry|June 12, 1992
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines P Sauerberg, P H Olesen, S Nielsen, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Current Opinion in Drug Discovery & Development|December 1, 2001
The use of bioisosteric groups in lead optimizationP H Olesen
Sygeplejersken|March 23, 1972
[Question without answer]P H Olesen
Current Medicinal Chemistry|April 3, 2001
Agonists at the alpha4beta2 nicotinic acetylcholine receptors: structure-activity relationships and molecular modellingJ E Tønder, P H Olesen
Bioorganic & Medicinal Chemistry|November 5, 1998
3-(5-Alkylamino-4-isoxazolyl)-1,2,5,6-tetrahydropyridines: a novel class of central nicotinic receptor ligandsP H Olesen, M D Swedberg, K Rimvall
Journal of Computer-Aided Molecular Design|April 6, 2001
An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled byJ E Tønder, P H Olesen, J B Hansen, et al.
Bioorganic & Medicinal Chemistry|July 15, 2000
Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptorsP H Olesen, J E Tønder, J B Hansen, et al.
Journal of Medicinal Chemistry|December 10, 1999
Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modelingJ E Tønder, J B Hansen, M Begtrup, et al.
Chirality|January 1, 1997
Synthesis and structural determination of stereoisomers of muscarinic ligands of the (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloalkane typeP H Olesen, P Sauerberg, T G Petersen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
M1 receptor agonist activity is not a requirement for muscarinic antinociceptionM J Sheardown, H E Shannon, M D Swedberg, et al.
Journal of Medicinal Chemistry|June 12, 1992
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines P Sauerberg, P H Olesen, S Nielsen, et al.
Pageof 3